Neurocrine Biosciences

The latest read

Computed from the data on Oct 22, 2026. Every figure links back to its source in the sections below.

• Revenue over the four quarters to June 30, 2026: $3.37 billion, up 34% from a year earlier.SEC EDGAR filings (XBRL)
• Free cash flow (operating cash flow minus capital expenditure) over the four quarters to September 30, 2025: $0.59 billion, up 34% from a year earlier.SEC EDGAR filings (XBRL)
• Capital expenditure over the four quarters to September 30, 2025: $0.04 billion, about level with a year earlier.SEC EDGAR filings (XBRL)
• Share buybacks in the fiscal year to December 31, 2025: $0.17 billion.SEC EDGAR filings (10-K)
• Latest earnings call or results release (July 30, 2026): sentiment 0.70 on a −1 to +1 scale (confident, opportunity-framed), confidence 0.80 of 1.Palanor Discourse
• Latest annual report (filed February 11, 2026): 2 risk factors added, 0 removed.Risk Factor Changes (10-K Item 1A)
• Insiders were net sellers in Q3 2026: $6.2 million on the open market.SEC Form 4
• 777 institutional managers reported a position at June 30, 2026 (+78 on the quarter before).SEC Form 13F
• H-1B filings certified in Q2 2026: 11 (4 a year earlier).U.S. Department of Labor (OFLC)

Company Posture covers S&P 500 companies.

No bond term sheets or tagged debt on file for Neurocrine Biosciences yet.

Charts

Live charts: each one redraws from today’s data and has an image link to paste into a document or slide.

In the news

Headlines that name Neurocrine Biosciences, with the publisher and a link. The tone is read from each headline’s own words, never from a summary of the article.

30 days

1 headlines

0% positive · 0% negative

90 days

2 headlines

0% positive · 0% negative

• Neutral
  STAT+: Concerns grow on safety issues tied to Neurocrine Biosciences rare disease drug

  STAT · Oct 13, 2026

• Neutral
  STAT+: Neurocrine Biosciences rare disease drug possibly tied to safety issues, experts say

  STAT · Aug 12, 2026

Filings and records

The last two years of notable 8-Ks, offerings, annual reports, federal awards, lobbying reports, patents and other public records, newest first.

1. Oct 20, 2026Lobbying
   Lobbying report (TARPLIN, DOWNS & YOUNG, LLC)third_quarter 2026 · $0.1 million
2. Oct 20, 2026Lobbying
   Lobbying report (BGR GOVERNMENT AFFAIRS)third_quarter 2026 · $0.1 million
3. Oct 20, 2026Lobbying
   Lobbying report (NEUROCRINE BIOSCIENCES, INC)third_quarter 2026 · $0.9 million
4. Oct 18, 2026Lobbying
   Lobbying report (CAPITOL COUNSEL LLC)third_quarter 2026 · $0.1 million
5. Sep 28, 20268-K
   Director or officer changeItem 5.02
6. Aug 26, 2026Trademark
   Trademark application: FACET
7. Jul 21, 2026Patent
   Patent granted: SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS CRF RECEPTOR ANTAGONISTSUS 12686680
8. Jul 20, 2026Lobbying
   Lobbying report (BGR GOVERNMENT AFFAIRS)second_quarter 2026 · $0.1 million
9. Jul 20, 2026Lobbying
   Lobbying report (TARPLIN, DOWNS & YOUNG, LLC)second_quarter 2026 · $0.1 million
10. Jul 20, 2026Lobbying
    Lobbying report (NEUROCRINE BIOSCIENCES, INC)second_quarter 2026 · $0.9 million
11. Jul 8, 2026Lobbying
    Lobbying report (CAPITOL COUNSEL LLC)second_quarter 2026 · $0.1 million
12. Jun 19, 2026Trademark
    Trademark application: STEP BACK INTO FOCUS
13. Jun 9, 2026Patent
    Patent granted: SUBSTITUTED PYRIDO[2,1-a]ISOQUINOLINES AS VMAT2 INHIBITORSUS 12649741
14. Jun 1, 2026Trademark
    Trademark application: DISCOVER CRENESSITY
15. May 28, 20268-K
    Director or officer changeItem 5.02
16. May 28, 20268-K
    Shareholder vote resultsItem 5.07
17. May 18, 20268-K
    Material agreement signedItem 1.01
18. May 18, 20268-K
    Acquisition or sale completedItem 2.01
19. May 1, 2026Trademark
    Trademark application: DISCOVERCAH
20. Apr 21, 2026Trademark
    Trademark application: THE SCIENCE OF FEELING ALIVE
21. Apr 6, 20268-K
    Material agreement signedItem 1.01
22. Feb 11, 202610-K
    Annual report (10-K)2 risk factors added, 0 removed
23. Dec 2, 2025Patent
    Patent granted: MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USEUS 12486250
24. Nov 24, 20258-K
    Director or officer changeItem 5.02
25. Sep 23, 2025Patent
    Patent granted: GPR52 MODULATORS AND METHODS OF USEUS 12421193
26. Aug 12, 2025Patent
    Patent granted: CRF RECEPTOR ANTAGONISTS AND METHODS OF USEUS 12383536
27. May 30, 20258-K
    Director or officer changeItem 5.02
28. May 22, 20258-K
    Director or officer changeItem 5.02
29. May 22, 20258-K
    Shareholder vote resultsItem 5.07
30. Apr 4, 20258-K
    Director or officer changeItem 5.02
31. Feb 10, 202510-K
    Annual report (10-K)4 risk factors added, 3 removed
32. Jan 27, 20258-K
    Material agreement signedItem 1.01
33. Feb 9, 202410-K
    Annual report (10-K)0 risk factors added, 4 removed

Peers

Companies in the same industry in the S&P 500, Russell 1000 or MidCap 400, closest in revenue first. Trailing twelve months, from SEC filings.

Identity

SEC CIK

914475

LEI

549300FECER0XBN49756

Wikidata

Q7002174